


AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. PM (DC-0251)									
Applicant(s): Wade and Demian													
Application No. 09/720,078	Filing Date July 25, 2001	Examiner Phillip Gambel	Customer No. 26259	Group Art Unit 1644	Confirmation No. 7302								
Invention: METHODS AND COMPOSITIONS FOR MODULATING ANTIGEN-SPECIFIC IMMUNOLOGICAL (HUMORAL) RESPONSES BY TARGETING SUCH ANTIGEN TO APCs IN CONJUNCTION WITH ANTI-CD40 LIGAND ADMINISTRATION													
<u>COMMISSIONER FOR PATENTS:</u>													
Transmitted herewith is an amendment in the above-identified application.													
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27													
The fee has been calculated and is transmitted as shown below.													
CLAIMS AS AMENDED													
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE								
TOTAL CLAIMS	6 -	31 =	0	x \$25.00	\$0.00								
INDEP. CLAIMS	1 -	4 =	0	x \$100.00	\$0.00								
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00								
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00								
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.													
 _____ Signature			Dated: July 6, 2006										
Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454			<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</td> </tr> <tr> <td colspan="2" style="height: 40px; vertical-align: bottom;">(Date)</td> </tr> <tr> <td colspan="2" style="height: 40px; vertical-align: bottom;">Signature of Person Mailing Correspondence</td> </tr> <tr> <td colspan="2" style="height: 40px; vertical-align: bottom;">Typed or Printed Name of Person Mailing Correspondence</td> </tr> </table>			I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on		(Date)		Signature of Person Mailing Correspondence		Typed or Printed Name of Person Mailing Correspondence	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on													
(Date)													
Signature of Person Mailing Correspondence													
Typed or Printed Name of Person Mailing Correspondence													
CC:													

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PM (DC-0251)
Inventor: Wade and Demian
Serial No.: 09/720,078
Filing Date: July 25, 2001
Examiner: Gambel, Phillip
Customer No.: 26259
Group Art Unit: 1644
Confirmation No.: 7302
Title: Methods and Compositions for Modulating
Antigen-Specific Immunological (Humoral)
Responses by Targeting Such Antigen to
APCs in Conjunction with Anti-CD40
Ligand Administration

Electronically Submitted via EFS-Web
Date: July 6, 2006

I hereby certify that this paper is being electronically
submitted on the date indicated above to the
Commissioner for Patents, U.S. Patent &
Trademark Office (Non-Fee Amendment).

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents
U.S. Patent & Trademark Office
(Non-Fee Amendment)

Dear Sir:

Reply Under 37 C.F.R. §1.111

This is a reply to the Office Action mailed April 11, 2006
setting a three (3) month statutory period for response. Please
enter the following amendments and remarks into the record.

Amendments to the Claims are reflected in the listing of
claims which begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.